Trails Edge Capital Partners, LP
ATLANTA, GA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$695.9M2026 Q3
Positions38
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.7%
What Changed This Quarter?
Top Holdings
LBRX
LB Pharmaceuticals
6.3%
BMRN
Biomarin Pharmaceutical
5.8%
NRIX
Nurix Therapeutics
5.4%
OBX
Obsidian Therapeutics
4.9%
IMCR
Immunocore
4.6%
FDMT
4D Molecular Therapeutics
4.6%
DSGN
Design Therapeutics
4.5%
CYTK
Cytokinetics
4.5%
New / Increased
9 new · 12 increased
OBXNEW
Obsidian Therapeutics
4.9%
TNGXNEW
Tango Therapeutics
3.9%
CLDXNEW
Celldex Therapeutics
3.6%
CTNMNEW
Contineum Therapeutics
3.3%
TYRANEW
Tyra Biosciences
3.1%
FTH
Faeth Therapeutics
4.0%
+82.7%
CYTK
Cytokinetics
4.5%
+63.1%
MLTX
Moonlake Immunotherapeutics
2.8%
+124.0%
Reduced / Exited
7 reduced · 6 sold out
TRAX
First Tracks Biotherapeutics
4.1%
-46.2%
LBRX
LB Pharmaceuticals
6.3%
-24.5%
OKUR
Onkure Therapeutics
0.2%
-56.9%
IRD
Opus Genetics
1.7%
-12.1%
XENE
Xenon Pharmaceuticals
2.1%
-9.1%
MIRMEXIT
Mirum Pharmaceuticals
4.2%
INSMEXIT
Insmed
3.9%
SNDXEXIT
Syndax Pharmaceuticals
3.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.